May 20 (Reuters) - German vaccine maker BioNTech

said on Tuesday that it plans to invest up to 1

billion pounds ($1.33 billion) over the next ten years to

broaden its research and development activities in partnership

with the UK government.

The company said its subsidiary BioNTech UK signed a grant

agreement with the UK government that builds on a multi-year

collaboration announced in January 2023.

Under the deal, BioNTech had undertaken to enroll up to

10,000 patients in clinical trials by the end of 2030 for

personalized cancer therapies and make investments to expand the

company's footprint in the United Kingdom.

BioNTech said on Tuesday that the UK will give the company a

grant of up to 129 million pounds ($172.05 million) for a period

of 10 years.

The company plans to use the grant to support its

establishment of two new R&D centers, the first of which will be

based in Cambridge and a second is currently being planned.

($1 = 0.7499 pounds)